 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Aug 25, 2009 |
| Title |
A Predictive Response Signature to Infliximab Treatment in Ulcerative Colitis |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Infliximab, an anti-TNFa monoclonal antibody, is an effective treatment for ulcerative colitis (UC) inducing over 60% of patients to respond to treatment. Consequently, about 40% of patients do not respond. This study analyzed mucosal gene expression from patients enrolled in ACT1 to provide a predictive response signature for infliximab treatment.
Keywords: predictive response signature
|
| |
|
| Overall design |
Twenty-two patients underwent colonoscopy with biopsy before infliximab treatment. Response to infliximab was defined as endoscopic and histologic healing at week 8 (P2, 5, 9, 10, 14, 15, 16, 17, 24, 27, 36, and 45 as responders; P3, 12, 13, 19, 28, 29, 32, 33, 34, and 47 as non-responders). Messenger RNA was isolated from pre-infliximab biopsies, labeled and hybridized to Affymetrix HGU133Plus_2.0 Array. The predictive response signature was verified by an independent data set.
|
| |
|
| Contributor(s) |
Li K, Baribaud F, Toedter G, Ma K, Song X, Marano C |
| Citation(s) |
19700435 |
| |
| Submission date |
Jul 25, 2008 |
| Last update date |
Mar 25, 2019 |
| Contact name |
K Li |
| E-mail(s) |
[email protected]
|
| Organization name |
Janssen R&D
|
| Street address |
1400 McKean Road
|
| City |
Spring House |
| State/province |
PA |
| ZIP/Postal code |
19477 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (23)
|
|
| Relations |
| BioProject |
PRJNA113623 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE12251_RAW.tar |
115.8 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...